This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
10 Aug 2015

Innova Biosciences Introduces Range of Conjugated Antibodies

Innova Biosciences has launched a range of conjugated antibodies. The unique range leverages Innova’s Lightning-Link and InnovaCoat bioconjugation technologies, to provide customers with antibodies conjugated to an extensive range of enzymes, fluorescent dyes and colloidal gold, for improved flexibility in experimental design.



The new range comprises 200 antibodies to nearly 30 different cardiac biomarkers, each available directly conjugated to 24 different enzymes, fluorescent dyes or nanoparticles. Innova intends to expand the range into other key research areas in the near future, catering to an increasingly wide scientific audience.



In conjunction with the new range, Innova has launched a new corporate website, to provide customers with easier online ordering facilities, as well as access to a range of resources and support materials. The website also features an Antibody Conjugate Generator tool, which enables customers ordering from the new conjugated antibodies range to select any desired cardiac marker, antibody clone and label.



The online Conjugate Generator provides Innova’s customers with unprecedented flexibility, speed and conjugation possibilities, enabling highly tailored reagents to be created at a fraction of the cost of a custom conjugation project.



Dr Nick Gee, CEO at Innova, said: "This new range represents a progression for Innova from our range of bioconjugation kits. For the first time we are offering antibodies, capitalising on our conjugation technologies to create a powerful new tool for researchers.”

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.